FDA Issues Advisory on Asthma Medications

June 17, 2008

The Food and Drug Administration has recently issued a public health advisory to highlight the correct use of asthma medications.  The AARC, at the request of the FDA, is getting the word out to respiratory therapists to be sure to discuss with patients and family members the correct use of inhaled asthma medications.

Of utmost concern to FDA officials is the reported incorrect use of Spiriva and Foradil capsules. There have been reports of patients swallowing the capsules rather than placing them in the inhalation devices. Officials at the FDA are working with manufacturers to improve the medication labeling and patient education for the correct use of these medications.

Also included in the health advisory is information on behavior/mood changes found with patients who take Singulair and the safety of Long-Acting Beta Agonists. The FDA Safety Update: Asthma Medications may be found at: www.fda.gov/consumer/updates/asthmameds051308.html.

“It is essential that patients are made aware of the adverse effects of taking respiratory medications in a manner in which it was not intended,” said Tom Kallstrom, AARC chief operating officer. “At the same time we need to provide our patients as well as other healthcare providers with the information they need so we can be assured they get the intended benefit of the medications and devices that deliver it.”

The AARC has been actively involved in providing the FDA with the AARC’s Aerosol Delivery Medication Guide.  This guide provides guidance and training for respiratory therapists. It discusses a wide range of aerosol inhalers including small volume nebulizers, metered-does inhalers (MDI) and MDI accessory devices, as well as dry powdered inhalers.